Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Essentials - Sleep Problems Complicated by Substance Use Disorders

    Contains 4 Component(s), Includes Credits

    This lecture will provide an overview of normal sleep followed by a detailed description of how SUDs impact it. Clinicians can use the information to educate and motivate their patients as part of the recovery plan. Nonpharmacologic suggestions will help clinicians provide evidenced based solutions.

    This lecture will provide an overview of normal sleep followed by a detailed description of how SUDs impact it. Clinicians can use the information to educate and motivate their patients as part of the recovery plan.
    Nonpharmacologic suggestions will help clinicians provide evidenced based solutions.

    Substance Use Disorders are one of the major medical disorders whether measured in personal, economic, or epidemiologic terms. All physicians will encounter patients with substance use disorders and primary care providers are the gateway to both initial treatment and subsequent referrals to specialists. This CME will provide participants with the knowledge, skills, and abilities to discuss substance use disorders with their patients in terms of how SUDs impact sleep and offer suggestions as part of a treatment plan that addresses sleep problems.

    Learning Objectives:
    1.Learn the basic elements of the sleep cycle.
    2.Learn how SUDs impact sleep and ways to improve the patients quality of life and recovery.


    R. Gregory Lande, DO, FAOAAM (Moderator)

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.

  • Essentials - Motivational Interviewing

    Contains 4 Component(s), Includes Credits

    Motivational Interviewing is a psychotherapy which helps individuals understand and manage their reluctance to change behavior. Overcoming this resistance is a fundamental step in helping individuals with a substance use disorder begin the process of recovery.

    Motivational Interviewing is a psychotherapy which helps individuals understand and manage their reluctance to change behavior. Overcoming this resistance is a fundamental step in helping individuals with a substance use disorder begin the process of recovery.

    Substance Use Disorders are one of the major medical disorders whether measured in personal, economic, or epidemiologic terms. All physicians will encounter patients with substance use disorders and primary care providers are the gateway to both initial treatment and subsequent referrals to specialists. This CME will provide participants with the knowledge, skills, and abilities to discuss substance use disorders with their patients and make informed treatment plans and referrals.

    Learning Objectives:
    1. Learn the basic elements of Motivational Interviewing.
    2. Engage the topic through video examples which will reinforce key concepts.


    R. Gregory Lande, DO, FAOAAM

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.

  • Essentials - Assessment of Patients with Substance Use Disorders

    Contains 4 Component(s), Includes Credits

    This course will focus on the screening, brief intervention and referral to treatment of the patients.

    There is strong evidence of the value and efficacy for universal screening for substance use problems in health care settings. The tenants of this model of care will be presented. There will be attention paid to integrating SBIRT into the primary care setting.

    Learning Objectives:

    1. The importance of universal screening for substance use disorders.
    2. The current validated models of SBIRT
    3. The foundation of engaging a patient in a brief intervention.


    R. Gregory Lande, DO, FAOAAM

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.

  • Essentials - Adolescent Substance Use- How to Recognize Screen and Communicate

    Contains 4 Component(s), Includes Credits

    Epidemiology & prevalence of drug use in young adults and teens and will include clinical pathways available for clinicians.

    Epidemiology and prevalence of drug use in young adults and teens and will include clinical pathways available for clinicians.

    Learning Objectives:
    1. Understand what drugs are used
    2. Accept data that outline frequency of use
    3. Options available to parents and teens for treatment

    Marla Kushner, DO, FACOFP, FASAM, FSAHM

    Dr. Marla Kushner graduated from the Michigan State University College of Osteopathic Medicine. She completed her Family Medicine residency at Botsford General Hospital in Farmington Hills, Michigan and completed an Adolescent/ Young Adult Medicine Fellowship at Chicago Osteopathic Hospital and Rush-Pres St. Lukes Hospital in Chicago. After her fellowship Dr. Kushner began working with adolescent substance abuse facilities in Chicago and received certification in Addiction Medicine from the American Society of Addiction Medicine and is a distinguished fellow of ASAM. She is a Diplomate in the American Board of Addiction Medicine.  Dr. Kushner received her fellowship in the American College of Osteopathic Family Physicians in March 2013 and is currently the medical director for New Hope Recovery Center in Chicago and two high school-based health centers in Chicago. She has a family medicine practice with a focus on adolescent and addiction medicine.

  • Essentials - Acute Post-Operative Pregnancy Pain with At-Risk Women

    Contains 4 Component(s), Includes Credits

    Attendees will gather an understanding of the ways to screen for Substance Use disorder in at-risk women and provide different ways to manage postpartum and post-operative pain.

    Attendees will gather an understanding of the ways to screen for Substance Use disorder in at-risk women and provide different ways to manage post-partum and post-operative pain.

     Learning Objectives:

    1. The attendee will learn Osteopathic Manipulative Medicine options to treat pregnant and post op women for pain.

    2. The attendee will learn how to assess for the risk of potential substance abuse in a pregnant or postoperative woman.

    3. The attendee will have an understanding of postpartum and pregnancy management that focuses on non-narcotic pain management when appropriate. 

    Marla Kushner, DO, FACOFP, FASAM, FSAHM

    Dr. Marla Kushner graduated from the Michigan State University College of Osteopathic Medicine. She completed her Family Medicine residency at Botsford General Hospital in Farmington Hills, Michigan and completed an Adolescent/ Young Adult Medicine Fellowship at Chicago Osteopathic Hospital and Rush-Pres St. Lukes Hospital in Chicago. After her fellowship Dr. Kushner began working with adolescent substance abuse facilities in Chicago and received certification in Addiction Medicine from the American Society of Addiction Medicine and is a distinguished fellow of ASAM. She is a Diplomate in the American Board of Addiction Medicine.  Dr. Kushner received her fellowship in the American College of Osteopathic Family Physicians in March 2013 and is currently the medical director for New Hope Recovery Center in Chicago and two high school-based health centers in Chicago. She has a family medicine practice with a focus on adolescent and addiction medicine.

  • Essentials - Assessment and Management of Tobacco Use Disorders

    Contains 4 Component(s), Includes Credits

    The World Health Organization has identified nicotine dependence as the number one preventable illness leading to the highest morbidity and mortality rates in the world. This presentation will review the epidemiology, the co-morbidity with behavioral health problem, and common screening and brief interventions in addressing the troubling problem with the patient. There will be a review of the FDA approved treatments.

    Nicotine dependence is the single greatest cause of morbidity and mortality in the world. It is important for all physicians and other health care workers to be well trained to be able to effectively engage patients in the discussion of abstinence. It is important that once the patient is engaged in trying to quit the physician or health care worker have an understanding of the evidence based treatments.

    Learning Objectives:

    1. Have and understanding of the impact nicotine dependence has on health.
    2. Understand ways in which a health care worker can approach the patient increasing the chance of behavior change.
    3. Understand the more common forms of treatment. There will be a discussion of "vaping” included n this section.

    R. Gregory Lande, DO, FAOAAM

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.

  • Essentials - Co-occurring and Substance Induced Disorders

    Contains 4 Component(s), Includes Credits

    There is a well-known association of mental health problems and the development and persistence of a substance use problem. This is often referred to as co-morbid illness.

    There is a well-known association of mental health problems and the development and persistence of a substance use problem. This is often referred to as co-morbid illness. This presentation will describe some of the more common associations of the two illnesses from both a developmental and neurobiologic perspectives. There will also be a presentation of the basic understanding of treatment of these patients.

    Learning Objectives:

    1. To have a better understanding of the origin of co-morbid illness.
    2. To understand some of the more common presentations.
    3. To understand the basic principles of treatment of the co-morbid patient.

    R. Gregory Lande, DO, FAOAAM

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 2/24/2020

    Contains 5 Component(s), Includes Credits Includes a Live Web Event on 02/24/2020 at 8:00 PM (EST)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions, please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance.The combined live webcast and online self-study training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided within 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 3/14/2020

    Contains 5 Component(s), Includes Credits Includes a Live Web Event on 03/14/2020 at 8:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 3/23/2020

    Contains 5 Component(s), Includes Credits Includes a Live Web Event on 03/23/2020 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions, please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance.The combined live webcast and online self-study training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided within 30 days after the training date.